Here are some of our most-listened-to 2020 "Not So Different" podcasts.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are some of our most-listened-to 2020 "Not So Different" podcasts.
Anurag Rathore, PhD, coordinator of the Center of Excellence for Biopharmaceutical Technology in Delhi, India, discusses findings from his study on biosimilar application failures.
Ryan Haumschild, PharmD, director of pharmacy at Emory Healthcare in Atlanta, Georgia, explains how a series of steps helped to increase biosimilar utilization within the Emory system and how these initiatives could be implemented on a larger scale.
Ha Kung Wong, an intellectual property law attorney and partner at Venable Fitzpatrick in New York, New York, and April Breyer Menon, an expert on biosimilar patent law and founder of April Breyer Consulting in Chicago, Illinois, discuss potential bills to improve biosimilar uptake and their chances for passage.
Christine Simmon, executive director of the Biosimilars Council and senior vice president of policy and strategic alliances at the Association for Accessible Medicines (AAM) in Washington, DC, discusses some of the advocacy changes the organization is looking to advance and their chances of approval.
Lastly, we spoke with Adrian van den Hoven, director general of Medicines for Europe, and Diogo Piedade, market access manager for Medicines for Europe, about their scorecard report for biosimilar access and what European markets they feel need the most work.
To read all these articles and more, visit centerforbiosimilars.com.
Biosimilars Policy Roundup for March 2023—Podcast Edition
April 2nd 2023On this episode of Not So Different, we discuss some of the global biosimilar policy news that came out during the month of March, including a new bill in Congress and 2 Canadian jurisdictions implementing switching policies.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
How Health Policy Can Impact Adoption for Adalimumab Biosimilars
September 25th 2022In this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, discussed current policy initiatives that could help biosimilar adoption and how the Inflation Reduction Act is expected to influence the adalimumab market.
Not So Different: Kathy Oubre on What Oncology Practices Have Lacked During the Pandemic
October 18th 2020We sat down with Kathy Oubre, chief operating officer at the Pontchartrain Cancer Center, to discuss what practices have had to forgo during the coronavirus disease 2019 (COVID-19) crisis and how biosimilar access has been affected.